Altimmune Net Income From Continuing Ops Over Time
| ALT Stock | USD 4.63 0.02 0.43% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Altimmune Performance and Altimmune Correlation. Altimmune | Build AI portfolio with Altimmune Stock |
Is there potential for Biotechnology market expansion? Will Altimmune introduce new products? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Altimmune's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Altimmune represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Altimmune's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare Altimmune and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (3 M) | (18.6 M) | (14 M) | (23.8 M) | (25 M) | (22.5 M) | (21.4 M) |
| BLRX | (17 M) | (17 M) | (17 M) | (17 M) | (11.1 M) | (14.4 M) | (15.8 M) | (24.4 M) | (23 M) | (25.4 M) | (30 M) | (27.1 M) | (25 M) | (60.6 M) | (9.2 M) | (8.3 M) | (8.7 M) |
| THAR | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (2.4 M) | (2.2 M) | (8.5 M) | (9.3 M) | (12.2 M) | (11 M) | (10.4 M) |
| AIMD | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (10 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| LPCN | 76.7 K | 76.7 K | 76.7 K | (10.6 M) | (20.4 M) | (18.2 M) | (19 M) | (21 M) | (11.7 M) | (13 M) | (21 M) | (634.4 K) | (10.8 M) | (16.3 M) | 8.4 K | 9.6 K | 10.1 K |
Altimmune and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Altimmune | ALT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 910 Clopper Road, |
| Exchange | NASDAQ Exchange |
USD 4.63
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.